BR0314526A - Composições farmacêuticas para o tratamento do mal de parkinson - Google Patents

Composições farmacêuticas para o tratamento do mal de parkinson

Info

Publication number
BR0314526A
BR0314526A BR0314526-3A BR0314526A BR0314526A BR 0314526 A BR0314526 A BR 0314526A BR 0314526 A BR0314526 A BR 0314526A BR 0314526 A BR0314526 A BR 0314526A
Authority
BR
Brazil
Prior art keywords
treatment
parkinson
disease
pharmaceutical compositions
salts
Prior art date
Application number
BR0314526-3A
Other languages
English (en)
Inventor
Michael Hawley
Michael S Bergren
Philip R Nixon
Gordon W Halstead
Robert Chao
Tzu-Chi R Ju
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0314526A publication Critical patent/BR0314526A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Abstract

"COMPOSIçõES FARMACêUTICAS PARA O TRATAMENTO DO MAL DE PARKINSON". A presente invenção refere-se a uma composição farmacêutica compreendendo um sal, de preferência um sal cristalino, de um ácido orgânico de baixa solubilidade em água e um composto de fórmula (1). Os sais são úteis no tratamento do mal de Parkinson. Também são fornecidos métodos de tratamento utilizando os sais e métodos de produção de formas cristalinas dos sais.
BR0314526-3A 2002-10-04 2003-10-02 Composições farmacêuticas para o tratamento do mal de parkinson BR0314526A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41629602P 2002-10-04 2002-10-04
PCT/US2003/031657 WO2004032854A2 (en) 2002-10-04 2003-10-02 Pharmaceutical compositions for treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
BR0314526A true BR0314526A (pt) 2005-07-26

Family

ID=32093840

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314526-3A BR0314526A (pt) 2002-10-04 2003-10-02 Composições farmacêuticas para o tratamento do mal de parkinson

Country Status (8)

Country Link
US (1) US20040138200A1 (pt)
EP (1) EP1546120A4 (pt)
JP (1) JP2006506360A (pt)
AU (1) AU2003277298A1 (pt)
BR (1) BR0314526A (pt)
CA (1) CA2500922A1 (pt)
MX (1) MXPA05003513A (pt)
WO (1) WO2004032854A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070219223A1 (en) * 2006-03-07 2007-09-20 Endacea, Inc. Compositions and methods for treating respiratory disorders
ES2452965T3 (es) * 2007-09-05 2014-04-03 Rigel Pharmaceuticals, Inc. Sal de xinafoato de N4-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-ona)-6-il]-5-fluoro-N2-[3-(metilaminocarbonilmetilenoxi)fenil]-2,4-pirimidindiamina
EP2085082A1 (en) * 2008-01-29 2009-08-05 Nutromnia S.R.L. Treatment of cognitive decline

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US5273975A (en) * 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
US5000962A (en) * 1989-08-25 1991-03-19 Schering Corporation Long acting diltiazem formulation
US5922342A (en) * 1990-10-01 1999-07-13 Pharmacia & Upjohn Company Lateral edge coated controlled release pharmaceutical compositions
SE9301057L (sv) * 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
CA2121435C (en) * 1993-04-16 2002-01-22 Sheila M. Ratnaraj Aqueous pharmaceutical suspension and process for preparation thereof
SE9604124D0 (sv) * 1996-11-12 1996-11-12 Pharmacia & Upjohn Ab Compact member, method of manufacturing and use thereof
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
DE10020517A1 (de) * 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
WO2001081343A2 (en) * 2000-04-21 2001-11-01 Pharmacia & Upjohn Company Compounds for treating fibromyalgia and chronic fatigue syndrome
AR033520A1 (es) * 2000-04-27 2003-12-26 Upjohn Co (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona
CA2413762A1 (en) * 2000-08-16 2002-02-21 Pharmacia & Upjohn Company Compounds for the treatment of addictive disorders
CA2435546A1 (en) * 2001-02-08 2002-08-15 Alice C. Martino Rapid-onset medicament for the treatment of sexual dysfunction
JP2005516020A (ja) * 2001-12-20 2005-06-02 ファルマシア・コーポレーション ゼロ次持続放出剤形およびその製造方法

Also Published As

Publication number Publication date
EP1546120A2 (en) 2005-06-29
CA2500922A1 (en) 2004-04-22
WO2004032854A2 (en) 2004-04-22
AU2003277298A8 (en) 2004-05-04
EP1546120A4 (en) 2006-11-22
AU2003277298A1 (en) 2004-05-04
JP2006506360A (ja) 2006-02-23
US20040138200A1 (en) 2004-07-15
MXPA05003513A (es) 2005-06-03
WO2004032854A3 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
BRPI0407262A (pt) Derivados de malonamida como inibidores gama-secretase
UA109774C2 (uk) Кристалічні форми саксагліптину та процес його одержання (варіанти)
BRPI0507786A (pt) composto e sais farmaceuticamente aceitáveis do mesmo, formulação farmacêutica, uso de um composto, método de tratar uma doença, e, processo para a preparação de compostos
BRPI0408369A (pt) derivados de indol úteis para o tratamento de doenças
BRPI0409969A (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
BRPI0410760A (pt) compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos
EA201171333A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
EA200700860A1 (ru) (бифенил)карбоновые кислоты и их производные
EA200401114A2 (ru) Замещённые гидроксиэтиламины
BRPI0511933B8 (pt) derivados de quinazolinona, seu uso e seu processo de preparação, e composição farmacêutica
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
NO20050088L (no) Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
DE602004014791D1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
BRPI0407695A (pt) compostos, processo para a preparação de um composto, composições farmacêuticas que compreendem o composto, utilização dos compostos e processo de tratamento para diabetes do tipo 2
SE0401970D0 (sv) Novel compounds
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
DE60311869D1 (de) Kristalline cefdinirsalze
AR075097A1 (es) Sales y formas polimorficas cristalinas de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea, composiciones farmaceuticas que las contiene, metodo para prepararlas y uso de las mismas en el tratamiento de enfermedades cardiovasculares asocia
BRPI0509667B8 (pt) composto, processo para a preparação de um composto de fórmula (i), medicamento e uso de um composto
EA200701852A1 (ru) Производные аминокислот
EA200601249A1 (ru) Пиперазины, пригодные для лечения боли
BRPI0511714A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para tratar uma doença em um animal
DK1606288T3 (da) Benzensulfonamidderivater, fremgangsmåde til fremstilling deraf og deres anvendelse til behandling af smerte

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]